The AR Gene Spinal and Bulbar Muscular Atrophy X-Linked Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the AR gene, which are responsible for Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease. This condition is an X-linked recessive disorder, meaning it predominantly affects males, though females can be carriers. SBMA is characterized by the degeneration of motor neurons in the spinal cord and brainstem, leading to muscle weakness and atrophy, as well as bulbar involvement that affects speech and swallowing.
The test involves analyzing the patient's DNA to identify specific mutations in the androgen receptor (AR) gene, which plays a crucial role in the development and maintenance of male characteristics. Mutations in this gene lead to the abnormal expansion of a CAG trinucleotide repeat, causing the neurological and muscular symptoms associated with SBMA.
Offered at a cost of 4400 AED, this genetic test is a critical tool for confirming the diagnosis of SBMA, enabling early intervention and management of the condition. It also provides essential information for family planning, as it can help identify carriers of the mutation who may be at risk of passing the condition to their offspring. Conducted at the state-of-the-art facilities of DNA Labs UAE, this test is a cornerstone in the personalized approach to genetic disorders, offering hope and support to affected individuals and their families.
The PLEKHG5 Gene Spinal Muscular Atrophy Distal Autosomal Recessive Type 4 Genetic Test is a specialized diagnostic examination designed to identify mutations in the PLEKHG5 gene, which are linked to the development of Spinal Muscular Atrophy Distal Autosomal Recessive Type 4 (DSMA4). DSMA4 is a rare genetic disorder characterized by muscle weakness and atrophy, primarily affecting the distal muscles closest to the center of the body, such as those of the feet and hands. This condition is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
The test is performed at DNA Labs UAE, a leading facility in genetic diagnostics, offering a comprehensive range of genetic testing services. The cost of the test is 4400 AED. The process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect the presence of mutations in the PLEKHG5 gene. This genetic test is crucial for the accurate diagnosis of DSMA4, enabling affected individuals and their families to understand their condition better and make informed decisions regarding management and treatment options. It also provides valuable information for genetic counseling, especially for families with a history of the disorder or those planning to have children.
The SMN1 Gene Spinal Muscular Atrophy Type 1 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to detect mutations in the SMN1 gene, which are indicative of Spinal Muscular Atrophy (SMA) Type 1. SMA Type 1, also known as Werdnig-Hoffmann disease, is a severe form of spinal muscular atrophy that manifests in infancy and is characterized by muscle weakness and atrophy resulting from the degeneration of motor neurons in the spinal cord. The test is crucial for early diagnosis and management of the condition, allowing for timely intervention and support for affected individuals and their families. Priced at 4400 AED, this genetic test provides a valuable tool for clinicians and genetic counselors in the assessment and understanding of this genetic disorder, paving the way for personalized treatment plans and improved patient outcomes.
The SMN1 Gene Spinal Muscular Atrophy Type 2 Genetic Test is a specialized diagnostic assessment available at DNA Labs UAE, designed to identify mutations in the SMN1 gene, which are indicative of Spinal Muscular Atrophy (SMA) Type 2. SMA Type 2 is a genetic disorder characterized by progressive muscle weakness and atrophy, typically manifesting in early childhood. This condition is caused by the loss or mutation of the survival motor neuron 1 (SMN1) gene, which is crucial for the maintenance and function of motor neurons.
The test, which costs 4400 AED, involves collecting a DNA sample from the patient, usually through a blood draw or cheek swab, and then analyzing the genetic material for specific mutations in the SMN1 gene. This precise genetic testing allows for an accurate diagnosis of SMA Type 2, enabling healthcare providers to tailor treatment plans and interventions to the specific needs of the patient. Early diagnosis through genetic testing is vital for managing symptoms, improving quality of life, and understanding the prognosis of the condition. DNA Labs UAE offers this test as part of its comprehensive suite of genetic diagnostic services, employing state-of-the-art technology and methodologies to ensure accurate and reliable results.
The SMN1 Gene Spinal Muscular Atrophy Type 3 Genetic Test is a specialized diagnostic tool designed to identify mutations in the SMN1 gene, which are indicative of Spinal Muscular Atrophy (SMA) Type 3. SMA Type 3, also known as Kugelberg-Welander disease, is a genetic disorder characterized by progressive muscle weakness and atrophy, primarily affecting the proximal muscles. This condition is caused by a reduction in the survival motor neuron protein due to mutations in the SMN1 gene.
This genetic test is crucial for early diagnosis, allowing for timely intervention and management of the condition. It involves analyzing the patient's DNA to detect the presence of specific mutations in the SMN1 gene that are responsible for SMA Type 3. Early diagnosis through this test can significantly impact the patient's quality of life, enabling access to supportive therapies and potential treatments that can slow the progression of the disease.
The test is available at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The cost of the SMN1 Gene Spinal Muscular Atrophy Type 3 Genetic Test is 4400 AED. DNA Labs UAE employs cutting-edge technology and highly qualified professionals to ensure accurate and reliable test results, providing crucial information for patients and their families to manage SMA Type 3 effectively.
The "SMN1 Gene Spinal Muscular Atrophy Type 4 Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, aimed at detecting mutations in the SMN1 gene, which are indicative of Spinal Muscular Atrophy (SMA) Type 4. SMA Type 4, also known as adult-onset SMA, is a rare genetic disorder characterized by progressive muscle weakness and atrophy, typically manifesting in adulthood. The test is crucial for individuals with a family history of SMA or those exhibiting symptoms, as it aids in confirming the diagnosis, understanding the disease progression, and making informed decisions about management and care. The test is conducted using a sample of the individual's DNA, extracted from a blood sample or cheek swab. At DNA Labs UAE, this comprehensive genetic analysis is offered at a cost of 4400 AED, providing invaluable insights into the genetic basis of SMA Type 4 and facilitating early intervention and personalized treatment strategies.
The DNAJB2 gene is closely associated with a form of spinal muscular atrophy (SMA) known as type 5. SMA type 5 is a rare genetic disorder characterized by progressive muscle weakness and atrophy, primarily affecting the motor neurons in the spinal cord. The DNAJB2 gene plays a crucial role in the maintenance and function of these neurons. Mutations in this gene can lead to the development of SMA type 5, making genetic testing for these mutations an important tool for diagnosis and family planning.
DNA Labs UAE offers a specialized genetic test for the DNAJB2 gene to help identify mutations that are associated with spinal muscular atrophy type 5. This test is crucial for individuals with a family history of SMA or those exhibiting symptoms related to motor neuron dysfunction. By analyzing the DNAJB2 gene, the test can confirm a diagnosis, allowing for early intervention and management strategies to be implemented. Additionally, it can provide essential information for families considering future pregnancies.
The cost of the DNAJB2 gene spinal muscular atrophy type 5 genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect mutations in the DNAJB2 gene accurately. Given the complexity of genetic testing and the specific expertise required to interpret the results, the cost reflects both the technological and professional resources involved in providing accurate and actionable information for patients and their families.
The ASAH1 Gene Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME) genetic test is a specialized diagnostic examination available at DNA Labs UAE, designed to identify mutations in the ASAH1 gene. These mutations are responsible for causing SMA-PME, a rare, autosomal recessive neurodegenerative disorder. The condition is characterized by progressive muscle weakness and wasting (spinal muscular atrophy) alongside myoclonic seizures (epilepsy). The test is crucial for early detection and management of the disease, offering insights into potential treatment paths and helping in family planning for those with a history of SMA-PME. The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed to ensure accurate results.
The ATP7A gene spinal muscular atrophy distal X-linked genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATP7A gene, which are linked to a rare form of spinal muscular atrophy (SMA) known as distal X-linked SMA. This condition affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy primarily in the distal muscles, which are those farthest from the center of the body, such as hands and feet. It is an X-linked disorder, meaning it is associated with the X chromosome, and typically affects males more severely than females.
DNA Labs UAE offers this comprehensive genetic test for individuals who may be at risk of carrying or expressing the mutation associated with this form of SMA. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the ATP7A gene.
The cost of the ATP7A gene spinal muscular atrophy distal X-linked genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the genetic analysis and the specialized expertise required to interpret the results accurately. By undergoing this test, individuals and families can gain valuable insights into their genetic health, enabling them to make informed decisions about their medical care and potential treatment options.
The BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 (SMA-LED2) genetic test is a specialized diagnostic tool used to detect mutations in the BICD2 gene, which are known to cause SMA-LED2. This condition is characterized by muscle weakness and atrophy predominantly affecting the lower limbs, often leading to difficulties in walking and mobility. It is inherited in an autosomal dominant pattern, meaning that only one copy of the altered gene is sufficient to cause the disorder.
The test is conducted at DNA Labs UAE, a reputable facility known for its comprehensive genetic testing services. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab to identify any mutations in the BICD2 gene.
The cost of the BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 genetic test is 4400 AED. While the price may seem steep, it's important to consider the value of the information it provides, which can be crucial for early diagnosis, management, and treatment planning for affected individuals and their families. Early detection through this genetic test can significantly improve the quality of life for those with SMA-LED2 by allowing for timely interventions and support.
